Objective: Lipodystrophy in HIV-1–infected antiretroviral-treated patients is often associated
with opposite alterations in adipose tissue depots as follows: lipoatrophy of subcutaneous …

Background The aetiopathogenic bases of HIV-1-/highly active antiretroviral treatment
(HAART)-associated lipodystrophy (HALS) are poorly known, but this syndrome indicates …

Objective To achieve a better understand of the pathophysiology of HIV-related lipoatrophy,
we compared the mRNA expression of adipocytokines in fat samples from patients and …

Lipodystrophy is a common alteration in HIV 1-infected patients under anti-retroviral
treatment. This syndrome is usually associated with peripheral lipoatrophy, central adiposity …

Background Lipodystrophy in HIV type-1 (HIV-1)-infected patients is the consequence of
effects originating from antiretroviral treatment and HIV-1 infection. We have studied adipose …

Objective: To determine the expressions of multiple genes in the subcutaneous adipose
tissue of HIV-positive, highly active antiretroviral therapy (HAART)-treated patients with and …

The lipodystrophy syndrome (adipose tissue redistribution and metabolic abnormalities)
observed with highly active antiretroviral therapy (HAART) during human immunodeficiency …

Context: The expression of adipogenic genes in sc adipose tissue has been reported to be
lower among patients with HIV-associated lipoatrophy than HIV-uninfected controls. It is …

Objective To determine whether the peripheral fat wasting (lipodystrophy), which is seen in
association with highly active antiretroviral therapy (HAART) that includes a nucleoside …

Objective: To determine liver fat content in patients with highly active antiretroviral therapy
(HAART)-associated lipodystrophy. Background: Lipodystrophy in several animal models is …